1 / 14

From Buffy Coat Platelets to Single Donor Platelets – A Feasibility Study

From Buffy Coat Platelets to Single Donor Platelets – A Feasibility Study. Dr. Sybesma, Sanquin Bloodbank Southeast, ‘s-Hertogenbosch, Netherlands St. Petersburg - June 9 th - 2004. Improvement of transfusion safety by reduction of donor exposure.

christopher-moss
Download Presentation

From Buffy Coat Platelets to Single Donor Platelets – A Feasibility Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. From Buffy Coat Platelets to Single Donor Platelets – A Feasibility Study Dr. Sybesma, Sanquin Bloodbank Southeast, ‘s-Hertogenbosch, Netherlands St. Petersburg - June 9th - 2004

  2. Improvement of transfusion safety by reduction of donor exposure • Variant Creutzfeldt-Jakob disease (Houston et al. 2000) • Septic platelet transfusion reactions (Ness et al. 2001) • Residual risk of viral infection (Soldan et al. 2003, Jackson et al. 2003) • HLA - (Slichter 1998) and HPA - refractoriness • TRALI • Unknown agents

  3.  Technical: donors selection: precount > 250, 70 kg Trima Accel, 100 procedures procedure time 70’ QC, splitting > 500  Economical: 434 Euro*pooled and single donor  Logistical: autosufficient 2500 PLT per year * nov 2002 Donors and methods

  4. TRIMA Accel

  5. Donorselection

  6. Number procedures per procedure time

  7. Form 289 procedures: Citrate reactions: Mild: 37, Moderate: 1, Severe: 0 Collaps: 0 Haematoma: 5 Hyperventilation: 0 Donor reactions

  8. Evolution - Real/Target Yield

  9. Evolution of split-rate (>500x10e9)

  10. Chronological trending of residual WBC levels

  11.  TRIMA: 6 procedures per day  50 weeks  190 donors  8 donations per year*  2600 SDP per year  18 % drop-out by out-dating * Lazarus et al. 2001 Logistical feasibility

  12. Donor satisfaction

  13. Cost price for SDP are less than revenues High split rates are beneficial for economical feasibility Revenues for SDP are higher than for BCP Cost of SDP are higher than for BCP Distribution of secondary costs over different components influence the cost of BCP Economical feasibility

  14.  Conversion is feasible economically, technically and logistically.  Adequate donor selection + high collection performence assure high split-rates in relatively short procedure time.  further research is needed on: how to keep donormotivation at high level donor recruitment and donor selection possibilities to reduce drop-out by outdating Cost / Qualy’s for pooled and apheresis PLT should be analyzed Conclusions

More Related